Browsing University of Hertfordshire by Author "Daneshmand, Siamak"

Now showing items 1-3 of 3

    • Erdafitinib in BCG-treated high risk non-muscle invasive bladder cancer 

      Catto, James W.F.; Tran, Ben; Roupret, Morgan; Gschwend, Juergen E.; Loriot, Yohann; Nishiyama, Hiroyuki; Redorta, Joan P.; Daneshmand, Siamak; Hussain, Syed A.; Cutuli, Hernan J; Procopio, Giuseppe; Guadalupi, Valentina; Vasdev, Nikhil; Naini, Vahid; Crow, Lauren; Triantos, Spyros; Baig, Mahadi; Steinberg, Gary D. (2024-01-30)
      Background: Treatment options are limited for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) with disease recurrence after bacillus Calmette–Guérin (BCG) treatment and who are ineligible for/refuse ...

    • Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer 

      D'Andrea, David; Black, Peter C.; Zargar, Homayoun; Zargar-Shoshtari, Kamran; Zehetmayer, Sonja; Fairey, Adrian S.; Mertens, Laura S.; Dinney, Colin P.; Mir, Maria C.; Krabbe, Laura Maria; Cookson, Michael S.; Jacobsen, Niels Erik; Montgomery, Jeffrey S.; Vasdev, Nikhil; Yu, Evan Y.; Xylinas, Evanguelos; Campain, Nicholas J.; Kassouf, Wassim; Dall'Era, Marc A.; Seah, Jo An; Ercole, Cesar E.; Horenblas, Simon; Sridhar, Srikala S.; McGrath, John S.; Aning, Jonathan; Wright, Jonathan L.; Thorpe, Andrew C.; Morgan, Todd M.; Holzbeierlein, Jeffrey M.; Bivalacqua, Trinity J.; North, Scott; Barocas, Daniel A.; Lotan, Yair; Grivas, Petros; Stephenson, Andrew J.; Shah, Jay B.; van Rhijn, Bas W.; Daneshmand, Siamak; Spiess, Philippe E.; Shariat, Shahrokh F. (2020-02-11)
      Objective: To assess the effect of patient's sex on response to neoadjuvant chemotherapy (NAC) in patients with clinically nonmetastatic muscle-invasive bladder cancer (MIBC). Methods: Complete pathologic response, defined ...

    • Phase 2 Study of the Efficacy and Safety of Erdafitinib in Patients With Bacillus Calmette-Guérin (BCG)-Unresponsive, High-Risk Non–Muscle-Invasive Bladder Cancer (HR-NMIBC) With FGFR3/2 Alterations (alt) in THOR-2: Cohort 2 Interim Analysis Results 

      Catto, James W.F.; Tran, Ben; Master, Viraj A.; Roupret, Morgan; Pignot, Geraldine; Tubaro, Andrea; Shimizu, Nobuaki; Vasdev, Nikhil; Gschwend, Juergen; Loriot, Yohann; Nishiyama, Hiyoyuki; Redorta, Joan; Daneshmand, Siamak; Miura, Yuji; Naini, Vahid; Crow, Lauren; Triantos, Spyros; Baig, Mahadi; Steinberg, Gary D. (2023-02-17)
      Patients presenting with NMIBC carcinoma in situ (CIS) have a high risk of progression1,2FGFR inhibition may benefit patients with CIS with FGFRalt who are unresponsive to fi rst-line BCG, for whom treatment options, other ...